Новые молекулы, исследуемые в качестве потенциальных ...

psychiatr.ru

15 май 2013 ... Новые молекулы, исследуемые в качестве потенциальных средств для лечения шизофрении На сайте Schizophrenia Research Forum опубликована сводная таблица всех новых молекул, которые.

REFRESH study: RP5063 shows promise for schizophrenia and...

www.news-medical.net

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH...

Schizophrenia: Information on schizophrenia and... | HealthCentral

www.healthcentral.com

Exposing Your Mental Illness in the Workplace. My schizophrenia diagnosis was disclosed via the employee newsletter. In 2004, I had won the...

Reviva Pharmaceuticals Announces Completion of Patient Enrollment...

revivapharma.com

Phase 2 study to assess the efficacy, safety and tolerability of RP5063 in male and female patients with schizophrenia.

RP-5063 - Wikipedia

en.wikipedia.org

RP-5063, also known as RP-5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

RP5063 in Subjects With Schizophrenia or... - ClinicalTrials.gov

clinicaltrials.gov

The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

RP-5063 - Pharmacodia

en.pharmacodia.com

神分裂症","indication":"Schizophrenia","profile":"A dopamine D2/D3/D4 receptor partial agonist, 5-HT1A/5-HT2A receptor partial agonist, 5-HT6/5-HT7 receptor antagonist potentially for the treatment...

Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for...

www.businesswire.com

RP5063 Phase 3 trials in schizophrenia measuring cognition outcome are in preparation.

REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter...

ichgcp.net

The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

Reviva Pharmaceuticals Announces Enrollment of Patients in Phase...

www.pipelinereview.com

Results from the Phase 1 clinical study of RP5063 conducted in the United States in 55 Caucasian and Asian subjects, both healthy volunteers and schizophrenia patients indicated that drug is...

RP-5063 - Howling Pixel

howlingpixel.com

RP-5063, also known as RP-5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective...

Поиск реализован с помощью YandexXML и Google Custom Search API